Enliven Therapeutics, Inc. Cash flow Statement
Figures in Million
Consolidated Cash Flow Results
Dec'25
Dec'24
Dec'23
Dec'22
Dec'21
Dec'20
No of Months
12
12
12
12
12
12
Profit Before Tax
-103.00
-88.00
-71.00
-37.00
-24.00
-41.00
Adjustment
0.00
0.00
0.00
0.00
0.00
0.00
Changes In working Capital
-1.00
-4.00
1.00
0.00
3.00
1.00
Cash Flow after changes in Working Capital
0.00
0.00
0.00
0.00
0.00
0.00
Cash Flow from Operating Activities
-70.00
-73.00
-61.00
-32.00
-19.00
-37.00
Cash Flow from Investing Activities
-173.00
-35.00
-148.00
0.00
0.00
-16.00
Cash Flow from Financing Activities
218.00
133.00
234.00
-1.00
-1.00
96.00
Net Cash Inflow / Outflow
-25.00
23.00
24.00
-34.00
-20.00
42.00
Opening Cash & Cash Equivalents
0.00
0.00
0.00
0.00
0.00
0.00
Cash & Cash Equivalent on Amalgamation / Take over / Merger
0.00
0.00
0.00
0.00
0.00
0.00
Cash & Cash Equivalent of Subsidiaries under liquidations
0.00
0.00
0.00
0.00
0.00
0.00
Translation adjustment on reserves / op cash balances foreign subsidiaries
0.00
0.00
0.00
0.00
0.00
0.00
Effect of Foreign Exchange Fluctuations
0.00
0.00
0.00
0.00
0.00
0.00
Closing Cash & Cash Equivalent
0.00
0.00
0.00
0.00
0.00
0.00
Figures in USD Million
Seasonal companies are compared with the same quarter last year
Seasonal companies are compared with the same quarter last year
Compare Cash Flow Results of Enliven Therapeutics, Inc.
Figures in Million
consolidated Cash Flow Results
Change(USD)
Change(%)
Profit Before Tax
-103.694
-299.614
196.00
65.39%
Adjustment
0
0
0.00
0.00%
Changes In working Capital
-1.121
22.992
-23.00
-104.88%
Cash Flow after changes in Working Capital
0
0
0.00
0.00%
Cash Flow from Operating Activities
-70.301
-241.104
171.00
70.84%
Cash Flow from Investing Activities
-173.841
194.286
-367.00
-189.48%
Cash Flow from Financing Activities
218.867
308.897
-90.00
-29.15%
Net Cash Inflow / Outflow
-25.275
262.079
-287.00
-109.64%
Opening Cash & Cash Equivalents
0
0
0.00
0.00%
Cash & Cash Equivalent on Amalgamation / Take over / Merger
0
0
0.00
0.00%
Cash & Cash Equivalent of Subsidiaries under liquidations
0
0
0.00
0.00%
Translation adjustment on reserves / op cash balances foreign subsidiaries
0
0
0.00
0.00%
Effect of Foreign Exchange Fluctuations
0
0
0.00
0.00%
Closing Cash & Cash Equivalent
0
0
0.00
0.00%
Cash Flow - Snapshot (Consolidated) - Dec'25
YoY Growth in year ended Dec 2025 is 3.95% vs -19.46% in Dec 2024
Dec'25
Dec'24
Change(%)
Cash Flow from Operating Activities
-70.30
-73.19
3.95%






